Yerushalmi, Rinat http://orcid.org/0000-0001-6221-2859
Pomerantz, Adi
Lewin, Ron
Paluch-Shimon, Shani
Soussan-Gutman, Lior
Baehner, Frederick L.
Voet, Hillary
Bareket-Samish, Avital
Kedar, Inbal
Goldberg, Yael
Peretz-Yablonski, Tamar
Kadouri, Luna
Funding for this research was provided by:
Oncotest
Exact Sciences
Article History
Received: 18 October 2023
Accepted: 24 January 2024
First Online: 3 April 2024
Declarations
:
: Financial interest: RY reported receiving fees from Roche (P.I, advisory board, invited speaker), Pfizer (P.I, advisory board), Novartis (advisory board, Invited speaker), Medison (advisory, invited speaker), MSD (invited speaker), Astra-Zeneca (P.I. advisory board, Invited speaker), Gilead Science (advisory board), and Eli Lilly (advisory board, invited speaker). SPS reported receiving fees from Roche (consultancy, advisory board, speaker’s bureau, travel), Novartis (consultancy, advisory board, speaker’s bureau), Eli Lilly (consultancy, advisory board), Gilead (consultancy, advisory board), MSD (consultancy, advisory board), Pfizer (consultancy, advisory board, speaker’s bureau, travel), Astra-Zeneca (consultancy, advisory board, speaker’s bureau), Exact Sciences (Speaker’s bureau), and Nanostring (Speaker’s bureau). LSG reported being employed at Rhenium Oncotest. FB reported being employed, having a leadership role, and stock ownership at Exact Sciences. HV reported being a consultant for BioInsight Ltd. ABS reported being a consultant for Mor, Pfizer, Can-Fite, Oncotest, and Exact Sciences. TPY reported receiving travel and accommodations from Medison and having a consulting/advisory role at Gilui, Progenetics, Cannabotech, Newstem, Gilead, Novartis, Janseen oncology, Pfizer, Msd, Lilly, Astra-Zeneca, Rhenium, and Dexel. LK reported receiving fees from Hoffman la Roche (research grant) and being a principal investigator at Eli Lilly, Bayer Pharmaceuticals, and Novartis. The remaining authors have declared no conflicts of interest (financial or nonfinancial).